EUVIMEDOpdag EUVIMED
Crossref

Antiproliferative Activity of the New Analogues of Acridine/Acridone With Oligopeptide Derivatives and Molecular Docking With EGFR and Src Kinase

Monika Gensicka-Kowalewska iD, Krystyna Dzierzbicka, Maria Skrzypkowska, Mateusz Daśko, Piotr Trzonkowski iD

Journal of Peptide Science · 2026

DOI: 10.1002/psc.70070 ↗

At a glance

Journal article in Journal of Peptide Science, 2026. Written by Monika Gensicka-Kowalewska and 4 co-authors. Institution: Department of Organic Chemistry, Gdansk University of Technology, Gdansk, Poland. Major MEDLINE topics: Acridines, ErbB Receptors, Molecular Docking Simulation, src-Family Kinases. Cited 1 times so far (Crossref); 25 references. Funded by: National Science Center (Poland).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The aim of our work was to analyze new functionalized analogues of 1‐nitroacridine/4‐methyl‐1‐nitroacridine and 4‐nitroacridone connected to tuftsin/retro‐tuftsin derivatives as a potential anticancer therapeutics. Using the MTT assay, we have evaluated the cytotoxic activity of synthesized analogues against the Jurkat cell line and healthy donor–isolated peripheral blood mononuclear cells (PBMCs). Jurkat cells were susceptible to several of the acridine derivatives, whereas PBMCs were sensitive to two compounds only. 4‐Methyl‐1‐nitro‐acridine analogue, classified as compound 28 , has exhibited the greatest anticancer potential with 4‐fold higher cytotoxicity toward Jurkat cells and 12‐fold lower cytotoxicity against PBMCs when compared with control therapeutics. Subsequent molecular docking analysis suggested that binding to epidermal growth factor receptor (EGFR) and proto‐oncogene tyrosine‐protein kinase Src molecules could be, at least partially, responsible for observed biological effects of created acridine/acridone analogues.

Subjects

MeSH terms (MEDLINE)

AcridinesErbB ReceptorsMolecular Docking Simulationsrc-Family KinasesAcridonesAntineoplastic AgentsOligopeptidesHumansCell ProliferationProto-Oncogene MasJurkat CellsLeukocytes, MononuclearStructure-Activity Relationship

Author keywords

EGFRSrcacridineacridoneanticancer agentsretro‐tuftsin

Substances

AcridinesErbB Receptorssrc-Family KinasesAcridonesMAS1 protein, humanProto-Oncogene MasAntineoplastic AgentsOligopeptidesEGFR protein, humanacridone

Authors and institutions

  • Department of Organic Chemistry, Gdansk University of Technology, Gdansk, Poland.
  • Department of Medical Immunology, Medical University of Gdansk, Gdansk, Poland.
  • Department of Inorganic Chemistry, Gdansk University of Technology, Gdansk, Poland.

ORCID profiles: Monika Gensicka-Kowalewska, Piotr Trzonkowski

Funding

  • National Science Center (Poland)

Cite

APA

Gensicka-Kowalewska, M., Dzierzbicka, K., Skrzypkowska, M., Daśko, M., & Trzonkowski, P. (2026). Antiproliferative Activity of the New Analogues of Acridine/Acridone With Oligopeptide Derivatives and Molecular Docking With EGFR and Src Kinase. Journal of Peptide Science. https://doi.org/10.1002/psc.70070

Vancouver

Gensicka-Kowalewska M, Dzierzbicka K, Skrzypkowska M, Daśko M, Trzonkowski P. Antiproliferative Activity of the New Analogues of Acridine/Acridone With Oligopeptide Derivatives and Molecular Docking With EGFR and Src Kinase. Journal of Peptide Science. 2026. doi:10.1002/psc.70070

BibTeX
@article{GensickaKowalewska2026,
  author = {Gensicka-Kowalewska, Monika and Dzierzbicka, Krystyna and Skrzypkowska, Maria and Daśko, Mateusz and Trzonkowski, Piotr},
  title = {Antiproliferative Activity of the New Analogues of Acridine/Acridone With Oligopeptide Derivatives and Molecular Docking With EGFR and Src Kinase},
  journal = {Journal of Peptide Science},
  year = {2026},
  doi = {10.1002/psc.70070}
}
Start for free →